166 related articles for article (PubMed ID: 17195078)
21. Characterization of fresh (uncultured) tumour-infiltrating lymphocytes (TIL) and TIL-derived T cell lines from patients with renal cell carcinoma.
Mitropoulos D; Kooi S; Rodriguez-Villanueva J; Platsoucas CD
Clin Exp Immunol; 1994 Aug; 97(2):321-7. PubMed ID: 8050183
[TBL] [Abstract][Full Text] [Related]
22. Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells.
Kurokawa T; Oelke M; Mackensen A
Int J Cancer; 2001 Mar; 91(6):749-56. PubMed ID: 11275975
[TBL] [Abstract][Full Text] [Related]
23. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.
Leisegang M; Turqueti-Neves A; Engels B; Blankenstein T; Schendel DJ; Uckert W; Noessner E
Clin Cancer Res; 2010 Apr; 16(8):2333-43. PubMed ID: 20371691
[TBL] [Abstract][Full Text] [Related]
24. Heteroconjugate antibody-directed killing of autologous human renal carcinoma cells by in vitro-activated lymphocytes.
Kerr L; Huntoon C; Donohue J; Leibson PJ; Bander NH; Ghose T; Luner SJ; Vessella R; McKean DJ
J Immunol; 1990 May; 144(10):4060-7. PubMed ID: 2139677
[TBL] [Abstract][Full Text] [Related]
25. Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation.
Finke JH; Rayman P; Hart L; Alexander JP; Edinger MG; Tubbs RR; Klein E; Tuason L; Bukowski RM
J Immunother Emphasis Tumor Immunol; 1994 Feb; 15(2):91-104. PubMed ID: 7907918
[TBL] [Abstract][Full Text] [Related]
26. Characterization of T-cell receptor V beta repertoire in ovarian tumour-reacting CD3+ CD8+ CD4- CTL lines.
Fisk B; Flytzanis CN; Pollack MS; Wharton JT; Ioannides CG
Scand J Immunol; 1994 Dec; 40(6):591-600. PubMed ID: 7848491
[TBL] [Abstract][Full Text] [Related]
27. Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes.
Schleypen JS; Von Geldern M; Weiss EH; Kotzias N; Rohrmann K; Schendel DJ; Falk CS; Pohla H
Int J Cancer; 2003 Oct; 106(6):905-12. PubMed ID: 12918068
[TBL] [Abstract][Full Text] [Related]
28. Impaired cytolytic activity in peripheral blood T cells from renal cell carcinoma patients.
Crocenzi TS; Tretter CP; Schwaab T; Schned AR; Heaney JA; Cole BF; Fisher JL; Ernstoff MS
Clin Immunol; 2005 Oct; 117(1):6-11. PubMed ID: 16027041
[TBL] [Abstract][Full Text] [Related]
29. Cellular immune response to human renal-cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones.
Bernhard H; Karbach J; Wölfel T; Busch P; Störkel S; Stöckle M; Wölfel C; Seliger B; Huber C; Meyer zum Büschenfelde KH
Int J Cancer; 1994 Dec; 59(6):837-42. PubMed ID: 7989126
[TBL] [Abstract][Full Text] [Related]
30. Existence of MHC class I-restricted alloreactive CD4+ T cells reacting with peptide transporter-deficient cells.
Kobayashi H; Kimura S; Aoki N; Sato K; Celis E; Katagiri M
Immunogenetics; 2001 Oct; 53(8):626-33. PubMed ID: 11797095
[TBL] [Abstract][Full Text] [Related]
31. CD3+CD56+CD8+ cells demonstrating a suppressor T cell-like function in the peripheral blood of colon cancer patients.
Akagi J; Takai E; Tamori Y; Ogawa M
Int J Oncol; 2001 Sep; 19(3):561-6. PubMed ID: 11494036
[TBL] [Abstract][Full Text] [Related]
32. Natural killer (NK)-like cytotoxic activity of allospecific T cell receptor-gamma,delta+ T cell clones. Distinct receptor-ligand interactions mediate NK-like and allospecific cytotoxicity.
Koide J; Rivas A; Engleman EG
J Immunol; 1989 Jun; 142(12):4161-8. PubMed ID: 2470816
[TBL] [Abstract][Full Text] [Related]
33. Renal Cell Carcinoma-Infiltrating CD3
Lee HW; Park C; Joung JG; Kang M; Chung YS; Oh WJ; Yeom SY; Park WY; Kim TJ; Seo SI
Curr Issues Mol Biol; 2021 May; 43(1):226-239. PubMed ID: 34071865
[TBL] [Abstract][Full Text] [Related]
34. T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts.
Demeure CE; Wolfers J; Martin-Garcia N; Gaulard P; Triebel F
Eur J Cancer; 2001 Sep; 37(13):1709-18. PubMed ID: 11527700
[TBL] [Abstract][Full Text] [Related]
35. Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma.
Kowalczyk D; Skorupski W; Kwias Z; Nowak J
Br J Urol; 1997 Oct; 80(4):543-7. PubMed ID: 9352689
[TBL] [Abstract][Full Text] [Related]
36. Human small intestinal mucosa harbours a small population of cytolytically active CD8+ alphabeta T lymphocytes.
Melgar S; Bas A; Hammarström S; Hammarström ML
Immunology; 2002 Aug; 106(4):476-85. PubMed ID: 12153510
[TBL] [Abstract][Full Text] [Related]
37. [Monitoring of anti-tumour cell-mediated response in patients with renal cell carcinoma, disturbance of T cell proliferation].
Lukesová S; Vroblová V; Hlávková D; Kopecký O; Vokurková D; Morávek P; Safránek H; Soucek P
Vnitr Lek; 2008 Feb; 54(2):139-45. PubMed ID: 23687704
[TBL] [Abstract][Full Text] [Related]
38. Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7-1 (CD8O) costimulation.
Wang YC; Zhu L; McHugh R; Graham SD; Hillyer CD; Dillehay D; Sell KW; Selvaraj P
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):1-8. PubMed ID: 9147700
[TBL] [Abstract][Full Text] [Related]
39. T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.
Andersen R; Westergaard MCW; Kjeldsen JW; Müller A; Pedersen NW; Hadrup SR; Met Ö; Seliger B; Kromann-Andersen B; Hasselager T; Donia M; Svane IM
Cancer Immunol Res; 2018 Feb; 6(2):222-235. PubMed ID: 29301752
[No Abstract] [Full Text] [Related]
40. HLA restriction and T-cell-receptor V beta gene expression of cytotoxic T lymphocytes reactive with human squamous-cell carcinoma of the head and neck.
Yasumura S; Weidmann E; Hirabayashi H; Johnson JT; Herberman RB; Whiteside TL
Int J Cancer; 1994 May; 57(3):297-305. PubMed ID: 8168988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
